HK1203823A1 - Method of treating diabetes using non-glycosylated apolipoprotein a-iv - Google Patents

Method of treating diabetes using non-glycosylated apolipoprotein a-iv Download PDF

Info

Publication number
HK1203823A1
HK1203823A1 HK15104317.1A HK15104317A HK1203823A1 HK 1203823 A1 HK1203823 A1 HK 1203823A1 HK 15104317 A HK15104317 A HK 15104317A HK 1203823 A1 HK1203823 A1 HK 1203823A1
Authority
HK
Hong Kong
Prior art keywords
methods
subject
need
expression system
glycosylated apolipoprotein
Prior art date
Application number
HK15104317.1A
Other languages
English (en)
Chinese (zh)
Inventor
Patrick Tso
Fei Wang
Sean Davidson
Original Assignee
University Of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/021802 external-priority patent/WO2012100010A1/en
Application filed by University Of Cincinnati filed Critical University Of Cincinnati
Publication of HK1203823A1 publication Critical patent/HK1203823A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK15104317.1A 2012-01-19 2012-11-21 Method of treating diabetes using non-glycosylated apolipoprotein a-iv HK1203823A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
WOPCT/US2012/021802 2012-01-19
PCT/US2012/021802 WO2012100010A1 (en) 2011-01-19 2012-01-19 Apolipoprotein aiv as an antidiabetic peptide
US201261675692P 2012-07-25 2012-07-25
US61/675,692 2012-07-25
PCT/US2012/066314 WO2013109342A1 (en) 2012-01-19 2012-11-21 Method of treating diabetes using non-glycosylated apolipoprotein a-iv

Publications (1)

Publication Number Publication Date
HK1203823A1 true HK1203823A1 (en) 2015-11-06

Family

ID=48799573

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104317.1A HK1203823A1 (en) 2012-01-19 2012-11-21 Method of treating diabetes using non-glycosylated apolipoprotein a-iv

Country Status (13)

Country Link
US (1) US9951120B2 (enExample)
EP (1) EP2804618B1 (enExample)
JP (1) JP6310398B2 (enExample)
KR (1) KR20140117565A (enExample)
CN (1) CN104066436B (enExample)
AU (1) AU2012366182B2 (enExample)
BR (1) BR112014017141A2 (enExample)
CA (1) CA2860782A1 (enExample)
EA (1) EA028230B1 (enExample)
HK (1) HK1203823A1 (enExample)
IL (1) IL233351A (enExample)
MX (1) MX357071B (enExample)
WO (1) WO2013109342A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012207301B2 (en) 2011-01-19 2016-05-19 University Of Cincinnati Apolipoprotein AIV as an antidiabetic peptide
AU2012366182B2 (en) 2012-01-19 2017-08-17 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein A-IV
JP6033433B2 (ja) 2012-07-25 2016-11-30 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法
AU2013295721B2 (en) 2012-07-25 2017-07-20 University Of Cincinnati Method of treating type I diabetes using apolipoprotein AIV
JP6629725B2 (ja) * 2014-06-23 2020-01-15 東亞合成株式会社 新規合成ペプチドおよびその利用
CN112546201A (zh) * 2019-09-26 2021-03-26 中国科学院生物物理研究所 人工脂蛋白颗粒apoA-Ⅳ脂肪体在治疗和/或预防糖尿病中的应用
CN113018459A (zh) * 2021-03-09 2021-06-25 百码科技(深圳)有限公司 一种基因治疗减肥的生物药剂及其制备方法
CN112891561A (zh) * 2021-03-09 2021-06-04 百码科技(深圳)有限公司 一种基因治疗脂肪肝的生物药剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2686605B1 (fr) * 1992-01-27 1994-03-11 Rhone Poulenc Rorer Sa Nouveaux polypeptides, leur preparation et leur utilisation.
WO1994027629A1 (en) 1993-05-28 1994-12-08 Merck & Co., Inc. Method to control appetite and treat obesity
US6729075B2 (en) * 2000-10-19 2004-05-04 Wenger Corporation Audience seating system
NZ537006A (en) 2002-05-17 2008-01-31 Esperion Therapeutics Inc The use of apolipoprotein A-I Milano, for the manufacture ofa composition for treating preventing or reducing ischemic reperfusion injury in a tissue or organ
EP2051725A4 (en) * 2006-07-11 2011-06-15 Harkness Pharmaceuticals Inc METHOD FOR THE TREATMENT OF GRAIN WITH SATURATION FACTORS
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2009116861A2 (en) * 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
CN103833712B (zh) 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶ii型、其制法和其药物组合物与用途
WO2012028522A1 (en) * 2010-08-30 2012-03-08 F. Hoffmann-La Roche Ag Alkaline feed
AU2012207301B2 (en) 2011-01-19 2016-05-19 University Of Cincinnati Apolipoprotein AIV as an antidiabetic peptide
AU2012366182B2 (en) 2012-01-19 2017-08-17 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein A-IV
AU2013295721B2 (en) 2012-07-25 2017-07-20 University Of Cincinnati Method of treating type I diabetes using apolipoprotein AIV
JP6033433B2 (ja) 2012-07-25 2016-11-30 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いて高血糖障害を治療する方法

Also Published As

Publication number Publication date
IL233351A0 (en) 2014-08-31
AU2012366182A1 (en) 2014-08-07
CN104066436B (zh) 2016-12-14
AU2012366182B2 (en) 2017-08-17
EP2804618B1 (en) 2018-03-07
IL233351A (en) 2016-12-29
JP2015506942A (ja) 2015-03-05
JP6310398B2 (ja) 2018-04-11
KR20140117565A (ko) 2014-10-07
MX357071B (es) 2018-06-22
AU2012366182A8 (en) 2015-06-18
EA028230B1 (ru) 2017-10-31
EP2804618A1 (en) 2014-11-26
MX2014008829A (es) 2014-10-24
CA2860782A1 (en) 2013-07-25
BR112014017141A2 (pt) 2019-09-24
US9951120B2 (en) 2018-04-24
EA201491369A1 (ru) 2015-03-31
US20150011469A1 (en) 2015-01-08
WO2013109342A1 (en) 2013-07-25
WO2013109342A8 (en) 2014-09-04
CN104066436A (zh) 2014-09-24

Similar Documents

Publication Publication Date Title
WO2013109342A8 (en) Method of treating diabetes using non-glycosylated apolipoprotein a-iv
PH12013500808A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
HK1211231A1 (en) Exendin-4 derivatives
WO2013166449A3 (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
WO2012115772A3 (en) Therapy for kidney disease and/or heart failure
ZA201503110B (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2014004993A3 (en) Methods of reducing ldl-p
WO2013186240A3 (en) Exendin-4 peptide analogues
MX2013005095A (es) Composicion farmaceutica, metodos de tratamiento y usos de la misma.
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
MX2020010004A (es) Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos.
WO2012012278A3 (en) Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex
BR112014027087A2 (pt) tablete, método para fabricação de um tablete de mesilato de bromocriptina, método para fabricação de um tablete de mesilato de bromocriptina e método de tratamento para melhorar o controle glicêmico de diabetes do tipo 2 em um paciente
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
EA201391063A1 (ru) Аполипопротеин a-iv в качестве антидиабетического пептида
WO2013025073A3 (ko) 유홍초 추출물을 함유하는 당뇨합병증 예방 또는 치료용 조성물
WO2008059041A3 (en) Complementation of factor xi deficiency by factor v mutants
WO2014018763A3 (en) Method of treating type i diabetes using apolipoprotein aiv
HK1209041A1 (en) A method of weight reduction
WO2014018079A8 (en) Method of treating hyperglycemic disorders using apolipoprotein aiv
WO2012116151A3 (en) Vinyl -aryl - sulfones for use in peritoneal carcinomatosis
WO2007147404A3 (de) Pharmazeutische zusammensetzung mit einem extrazellulären polyanion aus arthrospira
WO2012091425A3 (ko) 4-하이드록시 타목시펜 유사체 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는, 대사증후군 관련 질환의 예방 또는 치료용 조성물